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patients who are more likely to derive beneﬁt from the treatment.
Most of the biomarkers studies have focused so far on a) circulating
biomarkers, often unable to separate reactive responses of the host from
those of neoplastic lesions; and b) tissue biomarkers, based generally on
a single biopsy that do not account for the intrinsic heterogeneity ofAnti-angiogenic therapy
Breast cancer
RadiogenomicsMore than 45 years ago, Judah Folkman (Folkman, 1971) postulated
that proliferation, as well as the metastatic spread of cancer cells, de-
pend on the formation of a new vascular network, and that by cutting
off that blood supply a neoplastic lesion could be potentially starved
into remission. Decades later, this hypothesis led to the blooming of a
novel area of research, of an innovative approach to cancer treatment
and, in turn, to the development and validation of clinically approved
anti-angiogenic drugs such as the anti-VEGF monoclonal antibody
bevacizumab (Kerbel, 2008). Anti-angiogenic therapies have been ap-
proved for the treatment of several types of cancer but the mechanisms
of their anti-tumor activity remain incompletely understood (Jayson et
al., 2016; Bertolini et al., 2010).Moreover, the limited clinical beneﬁt re-
ported in several trials has called the initial enthusiasm into question. In
fact, in spite of potent anti-cancer activity reported in preclinical trials, a
meaningful improvement in the overall survival of patients has been
observed only in a few types of cancer, and almost all of the treated pa-
tients have experienced a clinical relapse (Kerbel, 2008; Jayson et al.,
2016; Bertolini et al., 2010). Clinically-efﬁcient anti-angiogenesis has
turned out to be more complex than originally thought for many rea-
sons: the multiple mechanisms employed by tumors to recruit blood
vessels; the heterogeneity inherent in all cancer subtypes; the complex-
ity of interactions between endothelial and pericyte vessel cells andm.2016.07.017.
.
en access article under the CC BY-NCother components of the microenvironment, and the lack of validated
predictive/prognostic biomarkers that could help clinicians to identify
multiple metastatic neoplastic lesions. With the recent emergence of
novel high-throughput technologies in the era of personalized therapy,
the ﬁeld of biomarker discovery continues to be the subject of intense
research. Innovative approaches in genomics, proteomics and multi-
parametric imaging have facilitated simultaneous analysis of clinical,
pathological, and genetic proﬁles alongwith the assessment of response
to the treatment.
Radiogenomics, a multidisciplinary approach aimed at creating a link
between molecular diagnostics and diagnostic imaging (Rutman & Kuo,
2009), is becoming an interesting emerging area of research,with the po-
tential to directly and signiﬁcantly inﬂuence clinical practice. The
radiogenomic approach could allow the identiﬁcation of robust, non-in-
vasive biomarkers based on patients' genomic, cellular and microenvi-
ronment alterations. This is potentially of paramount clinical relevance
to the design and implementation of clinical trials. Unfortunately, a very
limited number of trials have used and applied this approach so far. Pre-
liminary studies such as the one published here byMehta and coworkers
(Mehta et al., 2016), provide promising and potentially powerful new
tools for the understanding of tumor biology in terms of response to
anti-angiogenesis therapy and mechanisms of acquired resistance. This
might lead to the validation of predictive/prognostic and dynamic bio-
markers for clinical care. Authors took advantage of a well-designedwin-
dow-of-opportunity trial where 35 ductal breast cancer patients received
the anti-VEGF antibody bevacizumab alone, prior to neoadjuvant (i.e. be-
fore-surgery) chemotherapy. By means of correlative associations be-
tween Dynamic Contrast Enhanced-Magnetic Resonance (DCE-MRI)
parameters and changes in histological markers and gene expression,
Mehta et al. (Mehta et al., 2016) demonstrated that in responder patients,
the response to bevacizumabwas detectable even after a very short time
of treatment and was much more complex and heterogeneous than an-
ticipated, involving different pathways including angiogenesis (e.g.
ESM1 and FLT1), proliferation and cell death genes and proteins. In-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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related glycolysis, hypoxia, PI3K-Akt and immune checkpoint inhibition
signaling, suggesting a novel and potentially targetable adaptationmech-
anism of resistance.
Taken together, these features can be used as biomarkers for more
precise and earlier prediction of the biological features and prognosis
of breast cancers, so as to drive patient selection and enrollment in tai-
lored clinical trials. Most of all, this new insight on the molecular and
cellular mechanisms of resistance to the anti-VEGF treatment in breast
cancer might stimulate new combinatorial and sequential therapies
with anti-angiogenic, anti-PI3K and immune checkpoint inhibitors.
Anti-PI3K drugs and checkpoint inhibitors (such as anti-CTLA4, anti-
PD-1 and anti-PD-L1) are currently under clinical investigation in breast
cancer and in other types of malignancies. Unfortunately, in most cases
these new drugs are used alone and not in sequential and/or combina-
torial strategies.
Preliminary data by Mehta et al. (Mehta et al., 2016) need to be fur-
ther investigated for reproducibility and validated in larger cohorts of
patients, but results are already based on three different models show-
ing similar results. Because of the lack of validated predictive/prognostic
and/or dynamic biomarkers, the clinical use of bevacizumab in breast
cancer is nowadays much more limited (if used at all) than in the
early years after clinical approval in the US, EU and Asia (Bartsch et al.,
2015). These data suggest a possible re-evaluation of this drug basedupon early classiﬁcation of resistant/refractory patients. New innovative
clinical trials might now be designed taking into account the dynamic
monitoring suggested byMehta et al. (Mehta et al., 2016) and a combi-
nation approach with anti-PI3K and checkpoint inhibitors. Hopefully,
this approach might prolong the quality of life and the survival of the
limited number of breast cancer patients who are actually sensitive to
VEGF inhibition, while sparing other patients unnecessary, expensive
and sometimes toxic treatments.References
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